Quarterly ResultMay 5, 2026, 07:33 AM
Ocular Therapeutix Q1 Net Loss $(88.6)M; R&D Expenses Soar
AI Summary
Ocular Therapeutix reported a significant increase in net loss for the first quarter of 2026, reaching $(88.6) million, up from $(64.1) million in the prior year. This was primarily driven by a substantial rise in research and development expenses, which climbed to $66.2 million. Despite a slight increase in total revenue to $10.8 million, the company experienced a higher net cash outflow from operating activities, though it maintains a cash and cash equivalents balance of $666.7 million, expected to fund operations for at least the next 12 months.
Key Highlights
- Net loss for Q1 2026 was $(88.6) million, compared to $(64.1) million in Q1 2025.
- Total revenue, net, slightly increased to $10.8 million in Q1 2026 from $10.7 million in Q1 2025.
- Research and development expenses surged to $66.2 million in Q1 2026 from $42.9 million in Q1 2025.
- Net loss per share, basic, was $(0.40) in Q1 2026, compared to $(0.38) in Q1 2025.
- Cash and cash equivalents totaled $666.7 million as of March 31, 2026.
- Net cash used in operating activities increased to $(66.0) million in Q1 2026 from $(44.7) million in Q1 2025.
- Accumulated deficit reached $(1,245.6) million as of March 31, 2026.
- Product revenue, net, was $10.8 million in Q1 2026, up from $10.6 million in Q1 2025.
Price Impact
More from OCUL